Tonin Fernanda S, Tsuyuki Ross T, Fernandez-Llimos Fernando, Garcia-Cardenas Victoria, Laufs Ulrich, Schulz Martin
Pharmacy and Pharmaceutical Technology Department, Social and Legal Pharmacy Section, University of Granada, Granada, Spain.
Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB.
Can Pharm J (Ott). 2025 Aug 31:17151635251365148. doi: 10.1177/17151635251365148.
Pharmacist-led interventions have demonstrated benefits across various medical conditions; however, their impact on atrial fibrillation (AF) remains unexplored. This study aims to synthesize the available evidence regarding the pharmacist's role in AF management.
A systematic review with searches in PubMed, Scopus, and Web of Science was performed (PROSPERO: CRD42025647848). Randomized and non-randomized trials, as well as cohort studies reporting clinical, process, and humanistic outcomes, were included. Findings were pooled through pairwise meta-analyses. Dichotomous outcomes were reported as risk ratios (RRs) and continuous variables as standardized mean differences (SMDs) with 95% confidence intervals (CIs). The quality of the randomized and non-randomized studies was assessed using RoB 2.0 and ROBINS-I tools, respectively. Evidence was graded using the GRADE approach.
Seventeen studies ( = 11,428 participants) published between 2008 and 2024, predominantly as non-randomized trials/cohorts (77%), were included. Pharmacist-led interventions varied widely in scope, including anticoagulation management services, medication therapy management, and prescribing. Meta-analyses showed that pharmacists improved time in therapeutic range (SMD 0.35; 95% CI, 0.13-0.56) and reduced major bleeding events (RR 0.76; 95% CI, 0.61-0.95) and strokes (RR 0.65; 95% CI, 0.44-0.94) compared with usual care. Pharmacist care also increased appropriate prescription rates (RR 1.36, 95% CI, 1.18-1.56). No significant differences were found for other outcomes. Evidence was of low-to-moderate certainty.
Pharmacist-led interventions have been shown to improve certain clinical and process outcomes in AF.
High-quality randomized studies with well-defined interventions are still needed to better refine the pharmacist's role in AF care and to identify the most effective intervention in practice (see Graphical Abstract). 2025;158:xx-xx.
由药剂师主导的干预措施已在各种医疗状况中显示出益处;然而,其对心房颤动(AF)的影响仍未得到探索。本研究旨在综合有关药剂师在房颤管理中作用的现有证据。
进行了一项系统综述,检索了PubMed、Scopus和Web of Science(PROSPERO:CRD42025647848)。纳入了随机和非随机试验以及报告临床、过程和人文结局的队列研究。通过成对荟萃分析汇总研究结果。二分结局报告为风险比(RRs),连续变量报告为标准化均值差(SMDs),并带有95%置信区间(CIs)。分别使用RoB 2.0和ROBINS - I工具评估随机和非随机研究的质量。采用GRADE方法对证据进行分级。
纳入了2008年至2024年间发表的17项研究(n = 11428名参与者),主要为非随机试验/队列研究(77%)。由药剂师主导的干预措施在范围上差异很大,包括抗凝管理服务、药物治疗管理和处方开具。荟萃分析表明,与常规护理相比,药剂师改善了治疗范围内的时间(SMD 0.35;95% CI,0.13 - 0.56),减少了大出血事件(RR 0.76;95% CI,0.61 - 0.95)和中风(RR 0.65;95% CI,0.44 - 0.94)。药剂师护理还提高了适当处方率(RR 1.36,95% CI,1.18 - 1.56)。其他结局未发现显著差异。证据的确定性为低到中等。
已证明由药剂师主导的干预措施可改善房颤的某些临床和过程结局。
仍需要高质量的、干预措施明确的随机研究,以更好地明确药剂师在房颤护理中的作用,并确定实践中最有效的干预措施(见图摘要)。2025;158:xx - xx。